Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )

Size: px
Start display at page:

Download "Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )"

Transcription

1 Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )

2 Multiplate platelet function analysis in whole blood based on impedance aggregometry

3 Multiplate instrument 5 channels for parallel tests easy to use Windows XP based software automatic analysis and documentation duplicate sensor for internal quality control electronic pipetting

4 applications Multiplate is already one of the most widely used platelet function tests

5 Performing the test put the test cell into the measuring position attach the sensor cable pipette 300 µl of saline µl of blood* allow 3 minutes for warming and equilibration add the activator after 6 minutes: print the results discard the test cell * usually hirudin or heparin blood

6 Multiplate reagents comprehensive line of dedicated reagents

7 Multiplate tests 1/2 activation inhibition 1 release of arachidonic acid COLtest Collagen TXA 2 ASPItest Arachidonic Acid Aspirin NSAID TXA 2 ArA 1 COX TRAPtest TRAP ADPtest ADP resting platelet Clopidogrel Prasugrel Cangrelor PGE1 ADPtest HS (ADP + PGE1) platelet activation GpIIb /IIIa receptor exposure degranulation GpIIb/IIIa antagonists: Reopro (abciximab) Aggrastat (Tirofiban) Integrillin (Eptifibatid) activated platelet

8 Multiplate tests 2/2 test activation sensitivity not sensitive for ASPItest arachidonic acid: is converted to TXA2 by platelet-own cyclooxygenase aspirin, IIb/IIIa antagonists clopidogrel, vwf ADPtest ADP: binds onto platelet ADP receptors clopidogrel, IIb/IIIa antagonists aspirin, vwf ADPtest HS ADP + prostaglandin E1 (Prostaglandin is a natural inhibitor and enhances the sensitivity of the assay for clopidogrel) clopidogrel, IIb/IIIa antagonists aspirin, vwf TRAPtest TRAP-6 (thrombin receptor activating peptide): TRAP-6 is a potent agonist which mimicks the platelet-activating action of thrombin IIb/IIIa antagonists vwf, aspirin, clopidogrel (weak effect on TRAPtest) COLtest collagen: collagen activates platelet and triggers a release of arachidonic acid from the platelet membrane, which is converted to TXA2 by the Cyclooxygenase aspirin, IIb/IIIa antagonists clopidogrel, vwf RISTOtest Ristocetin: vwf dependent platelet activation via the GpIb receptor Bernard-Soulier syndrome, severe vwd, aspirin mild vwd

9 multiple electrode aggregometry = MEA - one Multiplate test cell incorporates two independent sensor units. - the increase of impedance due to the attachment of platelets to the electrodes is detected for each sensor unit separately and transformed to arbitrary aggregation units (AU) that are plotted against time. - the duplicate sensors serve as an internal control test during each measurement Pearson s correlation coefficient of single measurements of the curves assessed by the two electrode pairs and the difference of the two AUCs is calculated. The result is flagged if the values are outside of the acceptance range (correlation coefficient <0.98, difference to the mean curve >20%). D. Sibbing et al, Thromb Haemost Jan;99(1):121-6.

10 blood sample for Multiplate analysis - citrated blood is the typical sample anticoagulant used for platelet function analysis - citrate complexes approx. 98% of the free calcium in the sample - however calcium is an important second messenger of platelet activation - therefore citrate has the potential to disturb platelet function tests - for Multiplate analysis a tight attachment of platelets onto the impedance sensor is mandatory, which enhances the effect of calcium depletion on this method - therefore the analysis of blood anticoagulated by hirudin or heparin is recommended - hirudin blood collection tubes are commercially available from the manufacturer of Multiplate Since hirudin and other direct acting thrombin inhibitors do not reduce the concentration of divalent cations in plasma, these can be considered to provide a more physiological environment than the use of sodium citrate. On this basis, we would agree with the recommendation by Dynabyte that the use of hirudin or another direct acting thrombin inhibitor is preferable for measurements of platelet aggregation performed by MEA (multiple eletrode aggregometry = Multiplate). A. Johnson, Thromb Haemost Jun;99(6):

11 Why study platelet function in whole blood rather than in PRP? In PRP not all platelets may be present, the most active platelets and larger platelets may have been lost during centrifugation In PRP platelets are studied in isolation which is NOT their natural situation In whole blood other blood cells are also present - erythrocytes (a potential source of ADP and ATP and a means of removing adenosine) and leucocytes which also influence platelet aggregation. S. Heptinstal et al

12 examples TRAPtest ASPItest ADPtest no platelet inhibition 113 U 102 U 89 U 17 U 100 mg aspirin qd 139 U 134 U 75 mg clopidogrel qd 98 U 89 U 31 U 100 mg aspirin + 75 mg clopidogrel qd 88 U 8 U 17 U tirofiban (Aggrastat i.v.) 7 U 3 U 3 U

13 A.B. *1971 very weak aggregation in all tests due to Glanzman Thrombasthenia

14 near-patient application of Multiplate university clinic Frankurt / Main Hannover medical school Essen university clinic

15 Multiplate in interventional cardiology / neuroradiology

16 2 patients before and after aggrastat loading dose Aggrastat Aggrastat case report by Dr. med. Stefanie Müller-Schunk, Neuroradiologie, Klinikum der Universität München

17 2 patients before and after aspirin 500 mg i.v. aspirin 500 mg i.v. aspirin 500 mg i.v. 50 min after aspirin application case reports by Dr. med. Stefanie Müller-Schunk, Neuroradiologie, Klinikum der Universität München

18 increase of clopidogrel dose Nonresponse Response clopidogrel 75mg clopidogrel 2x75mg

19 change from clopidogrel to prasugrel Stent thrombosis AU AU 0 6 min Clopidogrel 150mg/d F. Krötz, Kardiologie, Klinikum der Universität München 0 6 min Prasugrel 10mg/d

20 Platelet Function Analysis Market simple whole-bloodbased 1-2 different tests available single chanel Multiplate complicated low standardisation used in research and reference labs cartridge-based platelet function tests easy-to-use multi-channel several tests available open system optical aggregometry flow cytometry

21 Summary Multiplate is one of the newer platelet function tests. The system has a high sensitivity for anti-platelet drugs (Aspirin, Clopidogrel, Prasugrel, IIbIIIa antagonists). It is widely used in laboratory and near-patient settings. Studies have shown a good predictivity towards thromboembolism in platelet non-responsiveness (10 fold enhanced risk for stent thrombosis in a study including 1608 patients following PCI). Studies have shown a predictivity for transfusion requirements during / after cardiac surgery. Further applications include the assessment of platelet disorders, drug interactions and animal models.

Multiplate platelet function analysis - application and interpretation

Multiplate platelet function analysis - application and interpretation Dr. Andreas Calatzis PD Dr. Michael Spannagl Department for Haemostasis and Transfusion Medicine Munich University Clinic Ludwig-Maximilians University Ziemssen Str. 1 80336 Munich, Germany calatzis@haemostasis.de

More information

Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing

Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing Paul Harrison Oxford Haemophilia & Thrombosis Centre Churchill Hospital Oxford, UK 10 th February 2011 Namur

More information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k103555 B. Purpose for Submission: New submission C. Measurand: Platelet aggregation D. Type of Test: Platelet aggregometer

More information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and

More information

Predictive power. Multiplate analyzer

Predictive power. Multiplate analyzer Predictive power Multiplate analyzer Multiplate analyzer Strengthening Roche s hemostasis portfolio With a series of industry firsts and innovative applications for early disease detection and monitoring,

More information

Annals of West University of Timisoara

Annals of West University of Timisoara Annals of West University of Timisoara Series of Chemistry 20 (1) (2011) 47-58 LABORATORY TESTING OF PLATELET FUNCTION BY AGGREGOMETRY: WHAT TEST SHOULD BE USED? Daniela Maximov a, Alina Lupu a, Cristiana

More information

Instructions for Use

Instructions for Use PN 14438.A.1 2012 09 14 Instructions for Use Technical Support: (US) 1 800 643 1640 (Outside US) +1 858 643 1600 MDSS: +1 858 643 1600 1 INTENDED USE The VerifyNow PRUTest is a whole blood test used in

More information

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001 L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and

More information

Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice

Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice Antiplatelets and oral anticoagulants Aspirin Plavix Prasugrel Ticagrelor Apixaban Rivaroxaban Dabigatran- Direct thrombin inhibitor

More information

Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field

Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field Coagulation and Transfusion Medicine / PLATELET FUNCTION TESTING Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field Lan Zhou,

More information

EVALUATION OF NOVEL LABORATORY METHODS USING WHOLE BLOOD TESTING IN DIFFERENT DISTURBANCES OF HAEMOSTASIS. Ph.D. thesis. Author: Dr.

EVALUATION OF NOVEL LABORATORY METHODS USING WHOLE BLOOD TESTING IN DIFFERENT DISTURBANCES OF HAEMOSTASIS. Ph.D. thesis. Author: Dr. EVALUATION OF NOVEL LABORATORY METHODS USING WHOLE BLOOD TESTING IN DIFFERENT DISTURBANCES OF HAEMOSTASIS Ph.D. thesis Author: Dr. Orsolya Tóth Program leader: Prof. Dr. Hajna Losonczy 1 st Department

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Surgery and Anti-Coagulation Agents

Surgery and Anti-Coagulation Agents CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment

More information

Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN

Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting Amy Huggins, BSN, RN Objectives 1 2 3 4 5 Recognize bleeding risk based on classes of IR procedures Differentiate

More information

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,

More information

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the

More information

Antithromboticthrombotic Monitoring

Antithromboticthrombotic Monitoring Introduction to Antithromboticthrombotic Monitoring 1 Topics What is thrombosis, and why is it significant? Coagulation Cascade Pathways of coagulation, anticoagulation, and fibrinolysis Thrombophilia

More information

23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist

23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist Implications for the Gastroenterologist Dr. Daniel Sadowski Royal Alexandra Hospital Edmonton, Ab. No financial interests I am not a hematologist 65 y.o. male referred for iron deficiency anemia (FIT positive)

More information

Per Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions

Per Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions Per Morten Sandset p.m.sandset@medisin.uio.no Hemostasis parameters and medication prior to radiological interventions The challenge Familial or acquired defects in the hemostatic system that dispose for

More information

Management of Patients on Anticoagulants. Haemostasis. Coagulation cascade. Cell-based model 19/11/2013

Management of Patients on Anticoagulants. Haemostasis. Coagulation cascade. Cell-based model 19/11/2013 Management of Patients on Anticoagulants National Coal Mining Museum 11 Nov 2013 Navneet Lad StR Special Care Dentistry Aims: Discuss the different anti-platelet drugs available. Discuss the new generation

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function

Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function British Committee for Standards in Haematology Writing group: Paul Harrison 1, Ian Mackie 2, Andrew Mumford 3, Carol

More information

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012 What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs Marvin A Wayne, MD, FACEP, FAAEM Associate Clinical Professor University of Washington, EMS Medical Director Whatcom County,

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director

More information

MultiplateT Analyzer für die Thrombozytenfunktionstestung. Literaturübersicht

MultiplateT Analyzer für die Thrombozytenfunktionstestung. Literaturübersicht MultiplateT Analyzer für die Thrombozytenfunktionstestung Literaturübersicht MultiplateT Analyzer Stärkung des Hämostaseportfolios Die Gerinnungsdiagnostik gehört fur Roche Diagnostics zu den wichtigsten

More information

NEW ANTIPLATELET AGENTS: An ideal platelet agent would have the following characteristics: 1. quick onset 2. reversible 3. benefit to patients 4.

NEW ANTIPLATELET AGENTS: An ideal platelet agent would have the following characteristics: 1. quick onset 2. reversible 3. benefit to patients 4. NEW ANTIPLATELET AGENTS: An ideal platelet agent would have the following characteristics: 1. quick onset 2. reversible 3. benefit to patients 4. universal response 5. excellent safety profile 6. able

More information

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015 Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic looks at hereditary platelet

More information

Review of Newer Antiplatelets, Antithrombotics and Reversal

Review of Newer Antiplatelets, Antithrombotics and Reversal Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in

More information

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. INDEX Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Acquired bleeding disorders, 37-57 acquired combined inhibitor to factor V and thrombin, 55 acquired

More information

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients

More information

Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.

Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. Royal College of Surgeons in Ireland e-publications@rcsi Molecular and Cellular Therapeutics Articles Department of Molecular and Cellular Therapeutics --0 Dual antiplatelet therapy unmasks distinct platelet

More information

INR = (patient PT/mean normal PT) ISI.

INR = (patient PT/mean normal PT) ISI. The Relationship of the International Normalized Ratio () to the Prothrombin Time (PT) By: William DePond MD, President and Chief Medical Officer MEDLAB In 1983, it was determined that patients receiving

More information

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about

More information

Antikoagulation und antithrombotische Therapie bei Herzerkrankungen

Antikoagulation und antithrombotische Therapie bei Herzerkrankungen Antikoagulation und antithrombotische Therapie bei Herzerkrankungen Christian Sticherling Kardiologie Dimitrios Tsakiris Hämatologie Einsatz der Antikoagulation und antithrombotischen Therapie in der Kardiologie

More information

Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy

Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy Papers in Press. Published October 3, 2014 as doi:10.1373/clinchem.2014.226332 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2014.226332 Clinical Chemistry 60:12 000 000

More information

Financial Disclosures. Learning Objectives 05/06/2015. None

Financial Disclosures. Learning Objectives 05/06/2015. None ANTITHROMBOTIC MANAGEMENT PRE AND POST ENDOSCOPY Dustin Loomes, MD, FRCPC, Advanced training in Inflammatory Bowel Disease University of Alberta Hospital, Edmonton, AB St. Paul s Hospital, Vancouver, BC

More information

Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding.

Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding. Learning Objectives Qualitative and Quantitative Platelet isorders Jeffrey S. Jhang, M.. Assistant Professor of Clinical Pathology College of Physicians and Surgeons New York, New York Understand the evaluation

More information

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013 EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12

More information

Inc. Wuhan. Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard (liquid) 2

Inc. Wuhan. Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard (liquid) 2 Uscn Life Science Inc. Wuhan Website: www.uscnk.com Phone: +86 27 84259552 Fax: +86 27 84259551 E-mail: uscnk@uscnk.com ELISA Kit for Human Prostaglandin E1(PG-E1) Instruction manual Cat. No.: E0904Hu

More information

Whole Blood Flow Cytometry

Whole Blood Flow Cytometry Whole Blood Flow Cytometry y Nailin Li Department t of Medicine, i Clinical i l Pharmacology Unit Karolinska Institute/University Hospital, 171 76 Stockholm Department of Pathology & Pathophysiology Zhejiang

More information

Clinical Guideline N/A. November 2013

Clinical Guideline N/A. November 2013 State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if

More information

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D. Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University

More information

The Society of Thoracic Surgeons (STS) Workforce on

The Society of Thoracic Surgeons (STS) Workforce on FROM STS WORKFORCE ON EVIDENCE BASED SURGERY 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations* Victor A. Ferraris,

More information

Platelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Platelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,

More information

An#- Coagulant An#- Thrombo#c An#- Platelet Drugs

An#- Coagulant An#- Thrombo#c An#- Platelet Drugs An#- Coagulant An#- Thrombo#c An#- Platelet Drugs 1 ANTICOAGULANT CLASSES INHIBITORS OF CLOTTING FACTOR SYNTHESIS WARFARIN (COUMADIN ) Rivaroxaban (Xarelto ) INHIBITORS OF THROMBIN HEPARIN, LEPIRUDIN (REFLUDAN

More information

Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko

Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko Review Platelet function testing in clinical diagnostics A. R. Rechner Assay Development Hemostasis, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany Schattauer 2011 79 Keywords Platelet

More information

Cyclooxygenase and NSAIDs

Cyclooxygenase and NSAIDs Cyclooxygenase and NSAIDs Cyclooxygenase An enzyme responsible for the production of prostaglandins Two forms, COX1 and COX2 Contains two separate active sites for prostaglandin synthase One side contains

More information

REVERSAL AGENT COMMENTS DIRECT THROMBIN

REVERSAL AGENT COMMENTS DIRECT THROMBIN GUIDELINE for ANTITHROMOBIC REVERSAL This document is intended as a guideline only and should not replace sound clinical judgment Table 1: Reversal for ANTICOAGULANT therapy ANTITHROMBOTIC REVERSAL AGENT

More information

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

New anticoagulants: Monitoring or not Monitoring? Not Monitoring The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information

Antiplatelet drugs, coronary stents, and non-cardiac surgery

Antiplatelet drugs, coronary stents, and non-cardiac surgery Antiplatelet drugs, coronary stents, and non-cardiac surgery Michael PJ DeVile BSc MB BS MRCP FRCA Pierre Foëx MA DPhil FRCA FMedSci FANZCA FSACA Matrix reference CPD 2C03 Key points Drug-eluting stents

More information

Thrombosis and Bleeding

Thrombosis and Bleeding Many questions, few answers Thrombosis and Bleeding Pierre Noel MD Mayo Arizona Scope of the Problem Thrombosis PV 12-39% ET 11-25% MF 10% 60-70% of thrombosis are arterial Splanchnic and cerebral thrombosis

More information

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology

More information

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University Platelet storage pool disease case discussions Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University Case I 29 yo WF presented for evaluation of possible platelet storage pool disease,

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Impact of new (direct) oral anticoagulants in patient blood management

Impact of new (direct) oral anticoagulants in patient blood management Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,

More information

Blood Management Today Incorporating TEG

Blood Management Today Incorporating TEG Blood Management Today Incorporating TEG AMSECT NABM meeting Mike Miller Manager Clinical Manager Hemostasis Training Haemonitics Rx Only 2011 Haemonetics Corporation. Haemonetics, TEG, RapidTEG and Thrombelastograph

More information

Canine creatine kinase MB isoenzyme (CK-MB)ELISA Kit

Canine creatine kinase MB isoenzyme (CK-MB)ELISA Kit Canine creatine kinase MB isoenzyme (CK-MB)ELISA Kit Catalog No. CSB-E15852c (96T) This immunoassay kit allows for the in vitro quantitative determination of canine CK-MB concentrations in serum and plasma.

More information

New Approaches to, and Indications for, Antiplatelet Therapy

New Approaches to, and Indications for, Antiplatelet Therapy New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

Lupus anticoagulant Pocket card

Lupus anticoagulant Pocket card Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss

More information

Como mejorar el manejo médico de los diabéticos con SCA

Como mejorar el manejo médico de los diabéticos con SCA DIABETES Y ENFERMEDAD CORONARIA EN 2011 Como mejorar el manejo médico de los diabéticos con SCA Antonio Fernández-Ortiz Jueves, 20 Octubre 2011 INSTITUTO CARDIOVASCULAR Conflicto de interés: Antonio Fernández-Ortiz

More information

Dorset Medicines Advisory Group

Dorset Medicines Advisory Group Shared Care Guideline for prescribing rivaroxaban in the prevention of adverse outcomes after acute management of acute coronary syndrome in adults INDICATION In accordance with NICE TA335 rivaroxaban

More information

PLATELETS: OVERVIEW. J. Kelton, M.D. May 3 rd, 2003

PLATELETS: OVERVIEW. J. Kelton, M.D. May 3 rd, 2003 PLATELETS: OVERVIEW J. Kelton, M.D. May 3 rd, 2003 HEMOSTASIS: A system to control blood loss from spontaneous or traumatic breaks in the blood vessel. THROMBOSIS: The formation of a blood clot within

More information

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /

More information

6 H2O + 6 CO 2 (g) + energy

6 H2O + 6 CO 2 (g) + energy AEROBIC RESPIRATION LAB DO 2.CALC From Biology with Calculators, Vernier Software & Technology, 2000. INTRODUCTION Aerobic cellular respiration is the process of converting the chemical energy of organic

More information

Medications in Stroke Rehabilitation THE GOALS OF PRESENTATION STROKE STATISTICS 9/9/2014

Medications in Stroke Rehabilitation THE GOALS OF PRESENTATION STROKE STATISTICS 9/9/2014 Medications in Stroke Rehabilitation THE GOALS OF PRESENTATION IDENTIFY POTENTIAL AREAS FOR PHARMACOLOGIC INTERVENTIONS IN THE STROKE REHAB PATIENT IDENTIFY AGENTS USED WITH GENERAL MECHANISM OF ACTION

More information

Hemostasis analyzer system

Hemostasis analyzer system Hemostasis analyzer system Providing fast, actionable results to help you reduce risks, complications and costs Get the whole picture with TEG Hemostasis analyzer system For more than forty years, hospitals

More information

What You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist

What You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Rational for secondary prophylaxis in VWD

Rational for secondary prophylaxis in VWD Rational for secondary prophylaxis in VWD Susan Halimeh Medical Thrombosis and Haemophilia treatment Center, Duisburg, Germany Dr. med. Susan Halimeh When is prophylaxis in patients with VWD recommended?

More information

Triple Versus Dual Antiplatelet Therapy After Coronary Stenting Impact on Stent Thrombosis

Triple Versus Dual Antiplatelet Therapy After Coronary Stenting Impact on Stent Thrombosis Journal of the American College of Cardiology Vol. 46, No. 10, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.07.048

More information

PFA-100 Platelet Function Analyzer In vitro method for platelet function testing

PFA-100 Platelet Function Analyzer In vitro method for platelet function testing PFA-100 Platelet Function Analyzer In vitro method for platelet function testing Clinical issue Insufficient bleeding tendency assessment before operation------- history taking, CBC,aPTT, PT, BT (Koscient

More information

Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit

Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit Catalog Number. CSB-E14405r For the quantitative determination of rat creatine kinase MM isoenzyme (CK-MM) concentrations in serum, plasma and tissue

More information

THE NEW GENERATION OF ORAL ANTICOAGULANTS

THE NEW GENERATION OF ORAL ANTICOAGULANTS THE NEW GENERATION OF ORAL ANTICOAGULANTS Joseph Sweeney MD FACP FRCPath Director, Transfusion Medicine and Coagulation Lifespan Academic Medical Center Professor of Pathology and Laboratory Medicine,

More information

New Oral Anticoagulants

New Oral Anticoagulants Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

Point-of-care testing Thrombelastography and platelet transfusion

Point-of-care testing Thrombelastography and platelet transfusion Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria Trauma-induced coagulopathy

More information

Hemostasis. Bleeding and Clotting. Hemostasis. Platelet Function. Platelet Degranulation Products

Hemostasis. Bleeding and Clotting. Hemostasis. Platelet Function. Platelet Degranulation Products Hemostasis Bleeding and Clotting Normal Hemostasis - Arrest of Bleeding Platelets Clotting/Coagulation Factors Blood Vessels /Vasculature Control of Hemostatic Mechanisms Properties of Normal Vascular

More information

Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit

Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit Rat creatine kinase MM isoenzyme (CK-MM) ELISA Kit Catalog Number. CSB-E14405r For the quantitative determination of rat creatine kinase MM isoenzyme (CK-MM) concentrations in serum, plasma, tissue homogenates.

More information

Laboratory Evaluation of Hemostasis

Laboratory Evaluation of Hemostasis Laboratory Evaluation of Hemostasis Roger S. Riley, M.D., Ph.D., Ann R. Tidwell, MT(ASCP) SH, David Williams, M.D., Ph.D., Arthur P. Bode, Ph.D., Marcus E. Carr, M.D., Ph.D. Table of Contents Table of

More information

New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS

New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

The introduction of foreign bodies into the blood stream,

The introduction of foreign bodies into the blood stream, Published March 15, 2012 as 10.3174/ajnr.A2963 REVIEW ARTICLE H.M. Hussein T. Emiru A.L. Georgiadis A.I. Qureshi Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures

More information

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center SCRN Medication Review Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center Objectives To explain the indications, contraindications, interaction, timing, dosing, side effects of: Thrombolytics

More information

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia

More information

Management of the new antiplatelets and anticoagulants

Management of the new antiplatelets and anticoagulants Management of the new antiplatelets and anticoagulants Session No.: 1 Name: C. Boustiere, T Ponchon Guidelines : Anti-thrombotic agents and digestive endoscopy 2006 : French guideline (SFED) 2007 : Japanese

More information